Chairman and Executive Director. Hong Kong, 11 February 2020
Chairman and Executive Director. As at the date of this announcement, the Board comprises (i) three executive Directors, namely, Xx. Xxxxx Xxxxxx, Xx. Xxxx Xxx and Mr. Xx Xxx, (ii) three non-executive Directors, namely, Mr. Xx Xxxxxx, Xx. Xx Xxxxxxx and Xx. Xxxx Xxxxxxx, and (iii) three independent non-executive Directors, namely, Xx. Xxxxx Xxxx Xxx, Mr. Au Xxxx Xxxx Xxxxxx and Mr. Xx Xxx.
Chairman and Executive Director. As at the date of this announcement, the Company’s executive Directors are Xx. Xxx Xxxx Xxxx Wilfred, J.P., (Chairman), Xx. Xxxx Shui Xxxxxx Xxx and Xx. Xxx Xxxx San; and the independent non-executive Directors are Xx. Xxxx Xxx Man, Xx. Xxxx Xxxx Xxxx and Xx. Xxxx Fu Kit Xxxxxx. This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and that there are no other matters the omission of which would make any statement herein or this announcement misleading.
Chairman and Executive Director. As at the date of this announcement, the Board comprises four executive Directors, namely Xx.
Chairman and Executive Director. As at the date of this announcement, the executive directors of the Company are Dr.
Chairman and Executive Director. Hong Kong, 21 January 2021 As at the date of this announcement, the executive directors of the Company are Dr. Xxx Xxxxxxxxx (Chairman), Xx. Xxx Xxxxxxxx (Deputy Chairman and Chief Executive Officer), Xx. Xxxxx Xxxxxxxxx, Xx. Xxxx Xxxx Xxxxx and Xx. Xxxx Xxxxxxx; the non-executive director of the Company is Xx. Xxx Xxx Ha; and the independent non-executive directors of the Company are Mr. Xxxxxxx Xxx, Xx. Xxxxx Xxx Xxxxx and Xx. Xxx Xxx. APPENDIX I — REPORT FROM REPORTING ACCOUNTANTS ON THE DISCOUNTED CASH FLOW FORECAST IN CONNECTION WITH THE VALUATION OF THE TARGET COMPANY 21 January 2021 To the Directors of Sihuan Pharmaceutical Holdings Group Ltd. We have been engaged to report on the arithmetical accuracy of the calculations of the discounted cash flow forecast (the “Forecast”) on which the valuation dated 21 January 2021 prepared by Xxxxx Xxxx LaSalle Corporate Appraisal and Advisory Limited in respect of Beijing Meiyan Space Biomedicine Co., Ltd.* (the “Target”) as at 31 December 2020 is based. The valuation is set out in the announcement of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”) dated 21 January 2021 (the “Announcement”) in connection with the subscription of shares of the Target. The valuation based on the Forecast is regarded by The Stock Exchange of Hong Kong Limited as a profit forecast under paragraph 14.61 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).
Chairman and Executive Director. Mr. Xxx Xxxx Xxx Associate Chairman, Executive Director and Chief Executive Officer: Xx. Xxxx Xxx Xxxx Executive Directors: Xx. Xxxxx Xxxx Xxxx Xx. Xx Xxxxx Xxxx Non-executive Director: Xx. Xxx Xxx X.
